Published in Hepatology on January 01, 2010
Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology (2012) 10.00
Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol (2010) 3.30
Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol (2013) 3.12
Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology (2011) 1.47
Coffee, alcohol and other beverages in relation to cirrhosis mortality: the Singapore Chinese Health Study. Hepatology (2014) 1.45
Coffee consumption and risk of cancers: a meta-analysis of cohort studies. BMC Cancer (2011) 1.37
Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroenterol (2011) 1.34
Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort. Gastroenterology (2014) 1.06
Caffeine inhibits the activation of hepatic stellate cells induced by acetaldehyde via adenosine A2A receptor mediated by the cAMP/PKA/SRC/ERK1/2/P38 MAPK signal pathway. PLoS One (2014) 1.02
The association of coffee intake with liver cancer incidence and chronic liver disease mortality in male smokers. Br J Cancer (2013) 0.99
Importance of hepatitis C virus-associated insulin resistance: therapeutic strategies for insulin sensitization. World J Gastroenterol (2010) 0.97
The etiology, diagnosis and prevention of liver cirrhosis: part 1 of a series on liver cirrhosis. Dtsch Arztebl Int (2013) 0.95
Pathophysiology of NASH: perspectives for a targeted treatment. Curr Pharm Des (2013) 0.95
Coffee drinking and pancreatic cancer risk: a meta-analysis of cohort studies. World J Gastroenterol (2011) 0.93
Nrf2 and Snail-1 in the prevention of experimental liver fibrosis by caffeine. World J Gastroenterol (2013) 0.91
Current concepts and management approaches in nonalcoholic fatty liver disease. ScientificWorldJournal (2013) 0.91
How does coffee prevent liver fibrosis? Biological plausibility for recent epidemiological observations. Hepatology (2014) 0.89
Caffeine protects against alcoholic liver injury by attenuating inflammatory response and oxidative stress. Inflamm Res (2010) 0.89
Insulin resistance and chronic liver disease. World J Hepatol (2011) 0.88
Interaction between hepatitis C virus and metabolic factors. World J Gastroenterol (2014) 0.87
I drink for my liver, Doc: emerging evidence that coffee prevents cirrhosis. F1000Res (2015) 0.85
Coffee Consumption Decreases Risks for Hepatic Fibrosis and Cirrhosis: A Meta-Analysis. PLoS One (2015) 0.85
Association between caffeine consumption and nonalcoholic fatty liver disease: a systemic review and meta-analysis. Therap Adv Gastroenterol (2016) 0.84
Reduced coffee consumption among individuals with primary sclerosing cholangitis but not primary biliary cirrhosis. Clin Gastroenterol Hepatol (2014) 0.83
Adenosine: tipping the balance towards hepatic steatosis and fibrosis. J Hepatol (2010) 0.82
Eligibility of persons who inject drugs for treatment of hepatitis C virus infection. World J Gastroenterol (2014) 0.82
Caffeine, a drug for all seasons. J Hepatol (2010) 0.79
Coffee provides a natural multitarget pharmacopeia against the hallmarks of cancer. Genes Nutr (2015) 0.77
Caffeine reduces hepatic lipid accumulation through regulation of lipogenesis and ER stress in zebrafish larvae. J Biomed Sci (2015) 0.77
Dietary history and physical activity and risk of advanced liver disease in veterans with chronic hepatitis C infection. Dig Dis Sci (2010) 0.76
Coffee consumption and NAFLD: a community based study on 1223 subjects. BMC Res Notes (2015) 0.76
Hepatoprotective and Anti-fibrotic Agents: It's Time to Take the Next Step. Front Pharmacol (2016) 0.76
Caffeine inhibits TGFβ activation in epithelial cells, interrupts fibroblast responses to TGFβ, and reduces established fibrosis in ex vivo precision-cut lung slices. Thorax (2016) 0.76
Aqueous Date Flesh or Pits Extract Attenuates Liver Fibrosis via Suppression of Hepatic Stellate Cell Activation and Reduction of Inflammatory Cytokines, Transforming Growth Factor- β 1 and Angiogenic Markers in Carbon Tetrachloride-Intoxicated Rats. Evid Based Complement Alternat Med (2015) 0.76
Coffee and liver - long way to go. J Clin Exp Hepatol (2012) 0.75
Coffee and Liver Disease. J Clin Exp Hepatol (2016) 0.75
The antifibrotic and fibrolytic properties of date fruit extract via modulation of genotoxicity, tissue-inhibitor of metalloproteinases and nuclear factor- kappa B pathway in a rat model of hepatotoxicity. BMC Complement Altern Med (2016) 0.75
A 90-Day Oral Toxicological Evaluation of the Methylurate Purine Alkaloid Theacrine. J Toxicol (2016) 0.75
Bioavailability of paracetamol with/without caffeine in Egyptian patients with hepatitis C virus. Eur J Clin Pharmacol (2016) 0.75
Coffee: The magical bean for liver diseases. World J Hepatol (2017) 0.75
Histological grading and staging of chronic hepatitis. J Hepatol (1995) 19.57
The relationship between green tea and total caffeine intake and risk for self-reported type 2 diabetes among Japanese adults. Ann Intern Med (2006) 4.67
Coffee drinking and hepatocellular carcinoma risk: a meta-analysis. Hepatology (2007) 3.22
Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States. Gastroenterology (2005) 3.12
Caffeine consumption. Food Chem Toxicol (1996) 2.84
Coffee consumption and risk of liver cancer: a meta-analysis. Gastroenterology (2007) 2.57
Coffee, cirrhosis, and transaminase enzymes. Arch Intern Med (2006) 1.90
Coffee consumption reduces the risk of hepatocellular carcinoma independently of its aetiology: a case-control study. J Hepatol (2005) 1.83
Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology (2005) 1.76
Coffee and serum gamma-glutamyltransferase: a study of self-defense officials in Japan. Am J Epidemiol (1994) 1.69
The relationship of coffee consumption with mortality. Ann Intern Med (2008) 1.65
Pharmacological application of caffeine inhibits TGF-beta-stimulated connective tissue growth factor expression in hepatocytes via PPARgamma and SMAD2/3-dependent pathways. J Hepatol (2008) 1.56
Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. J Natl Cancer Inst (2005) 1.37
Coffee consumption and decreased serum gamma-glutamyltransferase and aminotransferase activities among male alcohol drinkers. Int J Epidemiol (1998) 1.31
Coffee, tea, and caffeine consumption and incidence of colon and rectal cancer. J Natl Cancer Inst (2005) 1.30
Unexpected effects of coffee consumption on liver enzymes. Eur J Epidemiol (1993) 1.25
Coffee, caffeine, and the risk of liver cirrhosis. Ann Epidemiol (2001) 1.17
Does coffee protect against hepatocellular carcinoma? Br J Cancer (2002) 1.16
Coffee intake and mortality from liver cirrhosis. Ann Epidemiol (2003) 1.15
Coffee consumption and serum aminotransferases in middle-aged Japanese men. J Clin Epidemiol (2001) 1.13
Coffee consumption and the risk of primary liver cancer: pooled analysis of two prospective studies in Japan. Int J Cancer (2005) 1.10
Hepatoprotective and antioxidant effects of the coffee diterpenes kahweol and cafestol on carbon tetrachloride-induced liver damage in mice. Food Chem Toxicol (2007) 1.07
Coffee diterpenes prevent the genotoxic effects of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and N-nitrosodimethylamine in a human derived liver cell line (HepG2). Food Chem Toxicol (2005) 1.03
Induction of Nrf2-mediated cellular defenses and alteration of phase I activities as mechanisms of chemoprotective effects of coffee in the liver. Food Chem Toxicol (2007) 0.99
Induction of cancer chemopreventive enzymes by coffee is mediated by transcription factor Nrf2. Evidence that the coffee-specific diterpenes cafestol and kahweol confer protection against acrolein. Toxicol Appl Pharmacol (2007) 0.95
Green tea consumption in everyday life and mental health. Public Health Nutr (2005) 0.91
Effects of coffee and its chemopreventive components kahweol and cafestol on cytochrome P450 and sulfotransferase in rat liver. Food Chem Toxicol (2007) 0.90
Coffee drinking and serum gamma-glutamyltransferase: an extended study of Self-Defense Officials of Japan. Ann Epidemiol (1999) 0.87
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med (2005) 21.56
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA (2012) 7.62
The burden of selected digestive diseases in the United States. Gastroenterology (2002) 6.79
Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature (2005) 6.21
Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology (2004) 5.83
Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science (2014) 5.47
Comparisons of percentage body fat, body mass index, waist circumference, and waist-stature ratio in adults. Am J Clin Nutr (2008) 5.01
Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology (2003) 4.95
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology (2006) 4.90
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
The prevalence of celiac disease in the United States. Am J Gastroenterol (2012) 4.77
Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med (2014) 4.70
Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol (2002) 4.56
Daily activity energy expenditure and mortality among older adults. JAMA (2006) 4.36
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology (2007) 3.87
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology (2004) 3.61
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology (2010) 3.55
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (2009) 3.50
Acute liver failure: Summary of a workshop. Hepatology (2008) 3.49
Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology (2011) 3.46
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Management of hepatitis B: summary of a clinical research workshop. Hepatology (2007) 3.40
A genome-wide genetic screen for host factors required for hepatitis C virus propagation. Proc Natl Acad Sci U S A (2009) 3.37
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA (2011) 3.37
Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med (2008) 3.33
A multicenter study of the outcome of biliary atresia in the United States, 1997 to 2000. J Pediatr (2006) 3.32
Hepatitis C virus infection activates an innate pathway involving IKK-α in lipogenesis and viral assembly. Nat Med (2013) 3.24
Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet (2011) 3.18
Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States. Gastroenterology (2005) 3.12
Relationship of hepatitis C virus infection with diabetes in the U.S. population. Hepatology (2014) 3.04
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
Gastrointestinal involvement in chronic granulomatous disease. Pediatrics (2004) 2.80
Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology (2009) 2.78
Progression of fibrosis in chronic hepatitis C. Gastroenterology (2003) 2.77
The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology (2010) 2.75
Improvement in survival associated with adult-to-adult living donor liver transplantation. Gastroenterology (2007) 2.72
Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology (2002) 2.64
Outcomes of 385 adult-to-adult living donor liver transplant recipients: a report from the A2ALL Consortium. Ann Surg (2005) 2.64
Effects of antiviral therapy on the cellular immune response in acute hepatitis C. Hepatology (2004) 2.64
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63
Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology (2008) 2.63
Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med (2010) 2.61
Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population. Clin Gastroenterol Hepatol (2005) 2.51
Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation (2003) 2.48
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology (2010) 2.47
Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology (2011) 2.44
The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis. Gastrointest Endosc (2006) 2.43
The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology (2011) 2.42
Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology (2009) 2.41
Optimal therapy of hepatitis C. Hepatology (2002) 2.40
Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology (2011) 2.39
A survey of liver transplantation from living adult donors in the United States. N Engl J Med (2003) 2.37
Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human hepatoma cells. J Virol (2005) 2.33
Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology (2011) 2.33
A Canadian screening program for hepatitis C: is now the time? CMAJ (2013) 2.33
Outcomes of living donor liver transplantation for acute liver failure: the adult-to-adult living donor liver transplantation cohort study. Liver Transpl (2008) 2.30
Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology (2010) 2.28
Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology (2010) 2.28
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25
National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology (2002) 2.19
Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology (2013) 2.17
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials (2008) 2.17
HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology (2012) 2.08
Composite tissue allotransplantation: development of a preclinical model in nonhuman primates. Transplantation (2005) 2.08
Activity energy expenditure and incident cognitive impairment in older adults. Arch Intern Med (2011) 2.07
Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences. Ann Intern Med (2007) 2.07
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol (2003) 2.05
Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era. Hepatology (2011) 2.01
Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology (2011) 1.98
Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology (2010) 1.98
Relationship of non-alcoholic fatty liver disease with cholecystectomy in the US population. Am J Gastroenterol (2013) 1.95
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology (2005) 1.93
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology (2007) 1.92